Compare SoundHound AI Inc (SOUN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs TG Therapeutics Inc — how do they compare? SoundHound AI Inc trades at $6.5 (market cap $2.92B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 2.9× SoundHound AI Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| SOUN | TGTX | |
|---|---|---|
Market Cap | $2.92B | $8.53B |
Sector | Technology | Health |
52-Week High | $21.40 | $59.06 |
52-Week Low | $5.70 | $26.94 |
Enterprise Value | $2.72B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $6.57, down 2.52% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company demonstrates strong revenue growth with Q2 2026 revenue up 45% year-over-year to $61.9 million, though it remains unprofitable with a -67.45% net income margin. Recent completion of the LivePerson acquisition creates a leading conversational AI platform with projected 2026 revenue of $230-260 million.
While analyst consensus remains bullish with 75% buy ratings and $8.50 price target (29% upside), significant risks include persistent losses, high valuation multiples (P/S 13.57), and negative cash flow projections for 2026. The stock's heavy short interest (nearly 40%) reflects market skepticism about profitability timeline despite strong top-line growth.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
